Amount of eligible individuals: CDEC mentioned the uncertainty in the amount of individuals with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some clients that are categorized as having moderate or reasonable condition may have a intense bleeding phenotype, https://hemgenix27047.blogoscience.com/42171728/about-hemgenix